Las Vegas Sands Corp. is joining the S&P 500, replacing San Francisco-based drugmaker Nektar Therapeutics. The change will become effective before trading opens Oct. 3.
The casino and gaming company will be added to the S&P 500 Global Industry Classification Standard Casinos & Gaming Sub-Industry Index.
Meanwhile, Nektar will replace Sotheby's in the S&P MidCap 400, also effective prior to trading Oct. 3. The company, which develops therapies for cancer, autoimmune disease and chronic pain, will be added to the S&P MidCap 400 GICS Pharmaceuticals Sub-Industry index.
Art auction house Sotheby's is being acquired by BidFair USA LLC in a $3.7 billion deal.
S&P Dow Jones Indices and S&P Global Market Intelligence are owned by S&P Global Inc.
